Pyridostigmine

DRUG16 trials

Conditions

Colonic TransitConstipationDiabetes ComplicationsDiabetes MellitusFibromyalgiaGastric EmptyingHIVHIV Disease

Early Phase 1

Autonomic Neuropathy, GI Motility, and Inflammation in HIV

CompletedNCT02850276

Icahn School of Medicine at Mount SinaiHIV Disease

Start: 2015-11-30End: 2018-06-01Updated: 2019-05-29

Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS

CompletedNCT03261570

New York Medical CollegeOrthostatic Intolerance, Postural Orthostatic Tachycardia Syndrome (POTS), POTS

Start: 2017-07-01End: 2022-06-01Updated: 2022-09-28

Phase 1

Use of Pyridostigmine for Constipation in Diabetics

CompletedNCT00276406

Mayo ClinicColonic Transit, Constipation, Diabetes Mellitus +1

Start: 2006-05-31End: 2010-10-31Updated: 2012-11-30

AchE Inhibitor and Insulin

CompletedNCT03063515

University of MiamiDiabetes Mellitus

Start: 2017-04-19End: 2018-12-14Updated: 2019-02-27

Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV

CompletedNCT04353778

Icahn School of Medicine at Mount SinaiHIV, Non-HIV, Vagus Nerve Dysfunction

Start: 2020-08-03End: 2026-03-27Updated: 2026-08-18

Phase 2

A Study of Pyridostigmine in Postural Tachycardia Syndrome

RecruitingNCT00409435

Mayo ClinicPostural Tachycardia Syndrome

Start: 2006-10-01End: 2027-02-01Target: 50Updated: 2026-03-05

Testing Mestinon and Exercise in Fibromyalgia

CompletedNCT00535587

Oregon Health and Science UniversityFibromyalgia

Start: 2002-09-30End: 2008-06-30Updated: 2011-04-18

Droxidopa / Pyridostigmine in Orthostatic Hypotension

Enrolling by invitationNCT01370512

Mayo ClinicOrthostatic Hypotension

Start: 2011-11-01End: 2027-05-01Target: 30Updated: 2026-07-15

SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4

CompletedNCT02941328

UMC UtrechtKugelberg-Welander Disease, SMA, Spinal Muscular Atrophy

Start: 2015-12-31End: 2018-01-31Updated: 2018-02-05

LIFT: Life Improvement Trial

RecruitingNCT06366724

Brigham and Women's HospitalLong COVID, ME/CFS, PASC

Start: 2024-09-10End: 2026-11-30Target: 160Updated: 2025-10-22

Clinical Usefulness and Influence on Esophageal Motility of Pyridostigmine for Dysphagia in Systemic Sclerosis

WithdrawnNCT06915181

Universitair Ziekenhuis BrusselSystemic Sclerosis With Dysphagia

Start: 2023-12-01End: 2024-05-01Updated: 2025-04-08

Phase 3

Pyridostigmine and Amifampridine for Myasthenia Gravis

NCT05919407

Leiden University Medical CenterMyasthenia Gravis

Start: 2023-03-22End: 2024-09-22Target: 24Updated: 2023-06-26

Phase 4

Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis

NCT03510546

University of AarhusMyasthenia Gravis

Start: 2018-04-09End: 2021-08-31Target: 44Updated: 2018-04-27

Addition of Pyridostigmine to Conventional Management of Postdural Puncture Headache

CompletedNCT05969119

Ain Shams UniversityPostdural Puncture Headache

Start: 2023-07-25End: 2024-01-03Updated: 2024-09-04

Unknown Phase

Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients

CompletedNCT00953914

Hospital de Clinicas de Porto AlegreDiabetes Complications

Start: 2005-03-31End: 2010-05-31Updated: 2011-07-07

Congenital myopathy in Southern Africa

RecruitingPACTR202103700536808

University College LondonMusculoskeletal Diseases

Start: 2021-03-01Target: 12Updated: 2026-08-03

Related Papers

Pyridostigmine and low-dose naltrexone for ME/CFS: study protocol for the Life Improvement Trial (LIFT), a randomized, double-blind, placebo-controlled clinical trial

Trials2026-08-12

Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.

2026-04-07

Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.

2026-04-07

Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2–4

Brain Communications2022-12-0925 citations

Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2–4 (SPACE trial)

BMJ Open2018-07-0138 citations